InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,412.00
(
0.05%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.85
(
1.13%
)
Bitcoin
65,011.09
(
-2.22%
)
Post# of 252248
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: genisi post# 182919

Saturday, 10/18/2014 1:20:04 PM

Saturday, October 18, 2014 1:20:04 PM

Post# of 252248
>>why they've chosen to enroll very advanced patients not those with an earlier stage of the disease

One advantage of the later stage patients is they do indeed have AD. The earlier stage patients are likely a mix of various dementias and frail elderly patients in overall decline.

Ran across a company recently that is running a new Phase III in APOE4 patients only based on a subgroup analysis of an earlier failed trial.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up